

1 Sophisticated Prediction of Carotid-Plaque Vulnerability by Nanocluster Sensitized
2 High-resolution Vessel-Wall-Imaging Profile in Rabbit Atherosclerotic Model

3 Running title: A successful translation provide reasonable diagnostic readouts from animals

4

5 Authors

6 *Yan Gong¹, Menglin Wu², Dingwei Fu³, Yu Guo¹, Xiudi Lu⁴, Ying Zou⁴, Xiang Zhang⁵, Jinxia
7 Zhu⁶, Xianchang Zhang⁶, Xue Li^{2*}, Shuang Xia^{1*}*

8 Author affiliations

9 *¹Department of Radiology, Medical Imaging Institute of Tianjin, Tianjin First Central
10 Hospital, School of Medicine, Nankai University, Tianjin, 300192, China*

11 *²Department of Radiology, Second Hospital of Tianjin Medical University, Tianjin 300211,
12 China*

13 *³Department of Radiology, First Central Clinical College, Tianjin Medical University, Tianjin
14 300192, China*

15 *⁴Department of Radiology, First Teaching Hospital of Tianjin University of Traditional
16 Chinese Medicine, Tianjin, China National Clinical Research Center for Chinese Medicine
17 Acupuncture and Moxibustion, Tianjin, China*

18 *⁵Department of Radiology, Tianjin Nankai Hospital, Tianjin 300100, China*

19 *⁶MR Collaboration, Siemens Healthcare Ltd., Beijing 100102, China*

20 Correspondence`

21 *Shuang Xia, Department of Radiology, Medical Imaging Institute of Tianjin, Tianjin First
22 Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, China*

23 *Email: 5020200851@nankai.edu.cn*

24 *Xue Li, Department of Radiology, Second Hospital of Tianjin Medical University, Tianjin
25 300211, China*

26 *Email addresses: lixue1229@tmu.edu.cn*

27 Statement of equal author contribution

28 *Yan Gong, Menglin Wu and Dingwei Fu contributed equally to this study*

29 *Shuang Xia and Xue Li are co-correspondences*

30 Manuscript Type: Original Research

31 Sophisticated Prediction of Carotid-Plaque Vulnerability by Nanocluster Sensitized
32 High-resolution Vessel-Wall-Imaging Profile in Rabbit Atherosclerotic Model

33 Running title: A successful translation provide reasonable diagnostic readouts from animals

34

35 Abstract

36 OBJECTIVE: To innovatively developed a macrophage-target nanoparticle based
37 contrast-enhanced high-resolution magnetic resonance vessel wall imaging (HR-VWI)
38 strategy to characterize the plaques' vulnerable features on rabbits.

39

40 BACKGROUND: Lacking of sensitive and specific image-marker of HR-VWI leads this
41 technique depending upon the plaque morphological characteristics. Nanoparticle-based
42 contrast agents modified with targeting ligands allow amplifying MR signals of the interested
43 components. The key to successful translation is the requirement that conducting studies in
44 larger animals to provide reasonable diagnostic readouts.

45

46 METHODS: The HR-VWI enhanced with macrophage-targeted PP1-Au@GSH@Gd (GdMG)
47 nanoclusters (NCs) and the conventional Gadovist were utilized for the plaque vulnerability
48 evaluation by a systematic histogram analysis in atherosclerosis (AS) rabbit model.

49

50 RESULTS: Due to the compelling targeting capacity of GdMG NCs to foamy macrophages,
51 the contrast-to-noise ratio (CNR) from pre-injection baseline dramatically raised from 6.50 to
52 36.91 ($p < 0.001$), with an increment of 1.39-fold higher than that of the Gadovist approach.
53 Spearman's correlation test confirmed that the coefficient of variation (CV) derived from the
54 histogram analysis based on GdMG NCs HR-VWI was indeed positively linearly correlated
55 with pathology vulnerability index (VI_p) significantly ($p < 0.05$) with adjusted $R^2 = 0.775$.
56 Finally, mathematic formulas with histogram-derived parameters as variables were fitted to
57 quantitatively calculate the histogram vulnerability index (VI_H) with the strength of the
58 adjusted $R^2 = 0.952$ ($p < 0.001$), and Area under the curve (AUC) of 0.875 ($p < 0.001$) to
59 realize the *in vivo* and quantitative calculation of the plaque vulnerability.

60

61 CONCLUSION: Profiting from the splendid inflammation targeted capacity and excellent
62 MRI performance of GdMG NCs, as well as the highly quantitative characteristics of
63 histogram analysis, we disclosed that our established imaging protocol was able to identify
64 the plaques' vulnerability index that were comparable to pathological examinations in both
65 retrospective and prospective experiments.

66

67 Key Words

68 Atherosclerosis; plaque; high-resolution magnetic resonance vessel wall imaging; histogram;
69 macrophage-target nanoparticle.

70

71 Abbreviations List

72 Atherosclerosis = AS

73 GdMG NCs = Gd-modified macrophage-target gold nanoclusters

74 HR-VWI = high-resolution vessel wall imaging

75 PPI = a novel 16-mer peptide targeted scavenger receptor AI

76 SR-A = scavenger receptors A

77 TOF-MRA = time-of-flight magnetic resonance angiography

78 CV = coefficient of variation

79

80 **1. INTRODUCTION**

81 Ischemic stroke that attributed to thromboembolism caused by carotid atherosclerotic
82 plaque has represented a massive public health issue¹⁻³, with an estimated 6.5% increase in
83 mortality from 2015 to 2019⁴. These sudden ischemic strokes usually contribute to
84 unheralded rupture of high-risk atherosclerotic plaques. In this context, identification of
85 plaque features which pose a high risk of rupture in a noninvasive manner is of paramount
86 important for preventing acute vascular events. Among all the current imaging techniques,
87 contrast-enhanced high-resolution magnetic resonance vessel wall imaging (HR-VWI) has
88 been recognized as a promising imaging technique to track the arterial atherosclerosis by
89 depicting the plaque presence, size and morphology with submillimetre resolution. A useful
90 work in this term by our group has demonstrated that contrast-enhanced HR-VWI is a
91 compatible standard to digital subtraction angiography (DSA) on analyzing plaque
92 morphology stenosis, benefiting from its efficient suppression on surrounding fluid signals
93 and high temporospatial resolution⁵. Despite well appreciated advantages, the inherent
94 limitations of HR-VWI, especially lack of sensitive and specific MRI contrast agents, lead
95 this imaging technique being largely dependent on the morphological characteristics of the
96 plaques when stratifying atherosclerotic risk, severely hampering its application in preventing
97 acute vascular events. In some cases, the risk plaques appear completely normal without any
98 prior symptoms, and the changes of indicative biomarkers such as intraplaque hemorrhage
99 (IPH), lipid-rich necrotic core (LRNC), thin fiber cap are prerequisite required for
100 confirmation of the plaques' diagnosis⁶⁻⁸.

101 Tremendous efforts have been devoted to the development of MRI contrast agents to
102 diagnose atherosclerosis beyond morphological characteristics or physiological function

103 changes. Particularly, nanoparticle-based contrast agents with high surface-to-volume ratios
104 allow the surface layers to be modified with targeting ligands (e.g., antibodies, proteins,
105 peptides), for targeted local amplifying MR signals of the interested components⁹⁻¹¹. For
106 example, more recently, our groups reported the peptide functionalized nanoparticles that can
107 specifically target inflammatory macrophages in plaques for quantitatively characterizing the
108 activity of foamy burden at the molecular level in ApoE^{-/-} mice¹², providing a chance for the
109 utilization of nanoparticle-based contrast agents to predict the carotid plaque vulnerability¹³.
110 Although the MR signals generated by the nanoparticle-based contrast agents are associated
111 with the vulnerability of plaques, it still remains daunting gap between the pre-clinical
112 researches and large-scale clinical applications. One of those challenges is that overwhelming
113 majority of pre-clinical works is merely limited to proof-of-concept mouse studies. However,
114 the key to successful translation is the need to conduct studies in larger animals to provide
115 reasonable diagnostic readouts that differ from mouse studies. Another challenge is the
116 interpretation of the MR signal patterns still highly relies on the radiologists' expertise and
117 experience, which may reduce the reproducibility or consistency of diagnostic results, and
118 thereby impairing the long-term monitoring of atherosclerosis progression. Concurrently, a
119 paradigm shift in this field has gained momentum as new imaging strategies to provide useful
120 experience for the clinically translation.

121 To address this need, we report a nanoparticle (Gd-modified macrophage-target gold
122 nanoclusters, GdMG NCs) based imaging strategy that surmounts the aforementioned hurdles
123 to precisely predict the carotid plaque vulnerability on the medium-sized animal model (a
124 rabbit atherosclerotic model). Capitalizing on established work¹², we firstly confirmed the
125 HR-VWI performance of GdMG NCs *in vitro* and *in vivo*. Next, we innovatively developed a
126 systematic histogram-based imaging protocol to characterize the plaques' vulnerable features
127 through establishing the relationships between the sensitized HR-VWI histogram profile and
128 the histological vulnerability index. As anticipated, the *in vivo* performance of GdMG NCs
129 suggested that GdMG NCs could promote HR-VWI recognition of AS plaques, evaluating
130 plaque progression and simultaneously identifying the plaques' vulnerability index in a

131 noninvasive manner. Profiting from the splendid inflammation targeted capacity and
132 excellent MRI performance of GdMG NCs, as well as the highly quantitative characteristics
133 of histogram analysis, we disclosed that our established imaging protocol was able to identify
134 the plaques' vulnerability index that were comparable to pathological examinations in both
135 retrospective and prospective experiments.

136 **2. METHODS**

137 **2.1 SYNTHESIS OF GDMG NCS**

138 The synthesis of the PP1-Au@GSH@Gd NCs (GdMG NCs) followed a typical pattern. The
139 synthesis of GdMG NCs and *in vitro* parallel imaging experiment is analytically described in
140 Supplemental Material (*Synthesis of PP1-Au@GSH@Gd NCs*).

141

142 **2.2 ANIMAL MODEL OF ATHEROSCLEROTIC PLAQUE**

143 The plaque formation was induced by balloon injury on the rabbits left common carotid
144 artery (LCCA) and followed with continuously high-fat diet (HFD). The atherogenic rabbits
145 were intramuscularly anesthetized with ketamine (35 mg/kg), acepromazine (0.75 mg/kg),
146 and xylazine (5 mg/kg). During the procedure, anesthesia was maintained with isoflurane
147 inhalation. Rabbits were euthanized with an overdose of sodium pentobarbital (160 mg/kg
148 i.p.). The feeding protocol and surgery procedure was adequately described in Supplemental
149 Material (*Animal model of atherosclerotic plaque*).

150

151 **2.3 IN VIVO HR-VWI AND ANALYSIS**

152 The quantitative imaging measurements on the source images and the reconstructed images
153 for the vessel wall area (WA) (**Figure 2G**), and plaque area (PA) (**Figure 2G**) are given. The
154 contrast-to-noise ratios (CNR) and the contrast index (CI) were measured to reflect the
155 enhancement ability and nanoclusters deposition in the plaque region. The quantitative
156 histogram analysis of HR-VWI data was performed by segmenting the plaque and using the
157 freehand selection tool in the ImageJ software on HR-VWI (**Figure 4A**).¹⁴ The detailed
158 HR-VWI examination criteria, applied sequence protocol and analysis criteria are described
159 in the Supplemental Material (*In vivo HR-VWI and analysis, Standard workflow of image*
160 *interpretation* and **S. Table 1**).

161

162 **2.5 EX VIVO ANALYSES**

163 The histology staining for plaque tissue and the analysis criteria of pathology vulnerability
164 index (VI_p) for differentiating vulnerable plaques was meticulously described in the
165 Supplemental Material (*Ex vivo analyses*).

166 The characterization and stability study of GdMG NCs in combination with *in vivo*
167 security evaluation was also described in Supplemental Material (*Characterization of*
168 *PDA/Gd/Cu* and **S. Figure 1**), as has been reported in the previous works in the literature.¹⁵⁻¹⁷

169

170 **3. STATISTICAL ANALYSIS**

171 The continuous variables were reported as appropriate. The normality was assessed formally
172 by using the Shapiro-Wilk test. The advanced statistical methods were described in
173 Supplemental Material (*Statistical Analysis*).

174

175 **4. RESULTS**

176 **4.1 CONSTRUCTION OF THE ATHEROSCLEROTIC RABBIT MODEL**

177 The successful construction of the atherosclerotic rabbit model can be observed from **Figure**
178 **1** and were described in Supplemental Material (*Supplemental Results*).

179

180 **4.2 INVESTIGATION OF THE HR-VWI PERFORMANCE OF GDMG NCS**

181 In this work, for targeting the imaging foamy macrophage in plaque, the PP1-Au@GSH@Gd
182 NCs (GdMG NCs) was constructed by in situ reducing the Au atom into the zwitterionic
183 glutathione (GSH) shell with both Gd-DTPAA and PP1 peptide modification, which yielded
184 uniform size and a superior degree of dispersion. The characteristics of the prepared GdMG
185 NCs were described in (supplemental **S. Figure 1**). Then, the imaging property of GdMG
186 NCs on HR-VWI was investigated *in vitro* and *in vivo* (supplemental **S. Figure. 2**). From
187 these results, strong shreds of evidence were provided to verify the GdMG NCs could serve
188 as an ideal contrast agent for HR-VWI.

189 Encouraged by the superb performance of *in vitro* HR-VWI contrast capacity, the *in vivo*

190 foamy macrophage targeting and the selectivity efficacy of GdMG NCs on HR-VWI in
191 atherosclerotic rabbit models were next comprehensively quantified in comparison with
192 Gadovist (**Figure 2**). The results proved that GdMG NCs providing more definite
193 morphologic indices to identify the manifestation of culprit plaque-induced stenosis in
194 LCCAs compared with the Gadovist approach (detailed in *Supplemental Results, S. Figure 3*
195 **and S. Figure 4**). Consequently, from the Oil Red O, IHC staining, and silver-staining of the
196 LCCAs, significant lipid deposits and abundant foamy macrophages enrichment were
197 verified in the HR-VWI-highlighted regions induced by the GdMG NCs aggregation,
198 providing strong pieces of evidence for the compelling targeting capacity of GdMG NCs to
199 foamy macrophages in atherosclerotic plaques.

200

201 **4.3 THE REPRODUCIBILITY AND RELIABILITY OF PLAQUE EVALUATION BY** 202 **GDMG NCS ENHANCED HR-VWI**

203 Herein, the dynamic changes of the wall area (WA) and plaque area (PA) were also used to
204 quantify the collected imaging patterns (**Figure 3A**). For the progression of WA (**Figure 3C**)
205 and PA (**Figure 3D**) determined by the two different contrast agents, repeated measures
206 analysis of variance (RM ANOVA) was performed. By referring to the gold standard in the
207 histology of the H&E staining (supplemental **S. Figure 7**), the curve of GdMG NCs was
208 more steeply centered to the base axis ($x = 0$), indicating better accordance with the
209 histological analysis compared to Gadovist ($p < 0.05$) approach for the assessment of WA
210 (**Figure 3F**) and PA (**Figure 3G**) (supplemental material S. Table 3).¹⁸ The detailed results

211 Intra-observer, and inter-observer reproducibility of both GdMG NCs and Gadovist in the
212 quantification of WA and PA were described in Supplemental Material (*Supplemental*
213 *Results*).

214

215 **4.4 IN VIVO EFFECTS OF GDMG NCS ON PLAQUE VULNERABILITY** 216 **PREDICTION**

217 After revealing the superior competence of GdMG NCs in measuring the morphological
218 assessment for plaque, plaque vulnerability prediction studies were further conducted based
219 on the contrast-enhanced HR-VWI. **Figure 4** presents a graphical flowchart of the designed
220 method for the quantitative characterization of plaque vulnerability by histogram analysis
221 based on GdGM NCs enhanced HR-VWI *in vivo*. The pathology vulnerability index (VI_P),
222 which can be defined as the ratio of the destabilizing components (macrophage plus lipid) to
223 the stabilizing components (smooth muscle cell plus collagen), was used as the gold standard
224 for quantifying plaque vulnerability, with stable ($VI_P < 1.024$) and vulnerable ($VI_P \geq 1.024$)
225 groups¹⁹. VI_P emphasized the destabilized role of macrophage in plaque vulnerability, which
226 additionally reflected the plaque heterogeneity comprehensively. According to these
227 comprehensive criteria, histological-defined plaques were divided into vulnerable and stable
228 groups to retrospectively analyze their histogram characteristics on GdMG NCs enhanced
229 HR-VWI. As is illustrated in **Figure 5A**, the shapes of the histogram by GdMG NCs
230 dramatically varied in different plaque types. To quantify the histogram features in the
231 different plaque types, the kurtosis, skewness, and CV were utilized to clarify the correlation

232 between the signal intensity distribution and VI_P . The histological classification for plaque
233 vulnerability that corresponds to the image-colocalization in **Figure 5B** may provide clues to
234 the histogram features presented by vulnerable plaques. As can be observed from **Figure 5C**,
235 CV derived from GdMG NCs of vulnerable plaque was significantly higher than that of the
236 stable plaque ($p = 0.003$), indicating the existence of a more dispersed signal distribution
237 representing the heterogeneous enhancement (supplemental **S. Table 2**), which can be
238 explained by the above-mentioned enhancement mechanism related to the uneven distribution
239 of macrophages. Furthermore, from the Spearman's correlation test, it was confirmed that the
240 CV was indeed positively linearly correlated with VI_P significantly ($p < 0.05$) with adjusted
241 $R^2 = 0.775$ (**Figure 5D**, supplemental **S. Table 7**), implying a positive correlation between
242 CV and macrophage content as well. Comparatively, other indicators (kurtosis and skewness)
243 turned out to have no significant difference for dichotomous outcomes (stable vs vulnerable)
244 derived from GdMG NCs (supplemental **S. Figure 9**). Nonetheless, none of the histogram
245 parameters derived from the Gadovist method showed distinctions between stable and
246 vulnerable plaques ($p > 0.05$). Simultaneously, by considering the VI_P was time-dependent
247 (**Figure 5E**) ($p < 0.05$), both the GdMG NCs derived histogram parameters and
248 HFD-inducing period (Week) were introduced into the multiple linear regression analysis to
249 establish the non-invasive histogram vulnerability index (VI_H) for reasonable prediction.
250 Meanwhile, from the histological classification results with VI_P for the overall assessment of
251 plaque composition, an increasing proportion of vulnerable plaques during long-term HFD
252 intervention was demonstrated (supplemental **S. Figure 10**). Finally, two formulas were fitted

253 as follow: (model 1) $VI_H = 0.366 + 0.012\text{Week} + 1.361\text{CV}$, and (model 2) $VI_H = 0.226 +$
254 $0.005\text{Week} + 2.459\text{CV} - 0.019\text{kurtosis}$. In model 1, CV and Week contributed as variables to
255 calculate VI_H with adjusted $R^2 = 0.897$ ($p < 0.001$). Notably, the strength of model 2 was
256 stronger elevated with CV, kurtosis, and Week as the variables with different coefficients for
257 VI_H with adjusted $R^2 = 0.952$ ($p < 0.001$) (supplemental **S. Table 8**). Based on the
258 above-mentioned results, *in vivo* and quantitative calculation for plaque vulnerability was
259 realized by using histogram-defined parameters (histogram vulnerability index, VI_H) derived
260 from GdMG NCs enhanced HR-VWI.

261 Consequently, the diagnostic accuracy and prediction performance of VI_H , which was
262 calculated from the fitting formulas (models 1 and 2), was further prospectively investigated
263 in distinguishing vulnerable plaque *in vivo* with histology validation. For this reason, twelve
264 atherosclerosis rabbits were randomly chosen covering the whole HFD-inducing session and
265 were imaged by GdMG NCs enhanced HR-VWI for the VI_H evaluation. The
266 histogram-derived parameters based on GdMG NCs enhanced HR-VWI were next introduced
267 to the fitting formulas of the VI_H prediction. Then, the efficiency of the prediction results was
268 confirmed by the histological proof (VI_P) with a total number of 8 vulnerable plaques and 4
269 stable plaques. Supplemental S. Table 9 depicts the sum of 3 (3/8) lesions with $VI_H \geq 1.024$
270 that were precisely assigned to vulnerable plaques by using formula model 1, whereas model
271 2 detected 6 (6/8) vulnerable ones. On the contrary, 5 (5/8) vulnerable plaques were
272 misestimated as stable lesions by using the formula model 1, and only 2 (2/8) were
273 misestimated by model 2. Meanwhile, 4 stable plaques were all accurately recognized by

274 both formulas. The above-mentioned results indicated that formula model 2 had a higher
275 discriminative power in identifying the high-risk vulnerable plaques. The ROC analysis
276 (**Figure 5G**) was also conducted to examine the diagnostic performance of the two models in
277 determining the vulnerability of each lesion against the reference standard (VI_P). What's more,
278 Model 2-defined improved the diagnostic accuracy with an AUC value of 0.875 ($p < 0.001$),
279 which was 1.27-fold higher than model 1 (AUC = 0.688, $p = 0.040$). Additionally, as an
280 image-mediated diagnostic protocol, both sensitivity and specificity for potential risk
281 prediction should be aimed to improve. The table in **Figure 5G** illustrated the significantly
282 elevated diagnostic sensitivity of model 2 with respect to model 1 (75.0% vs 37.5%),
283 maintaining the perfect diagnostic specificity (100% vs 100%) as well.

284

285 **4.5 DIAGNOSIS AND PREDICTION OF VULNERABLE PLAQUE VIA** 286 **NANO-ENHANCED IMAGING VULNERABILITY INDEX**

287 The representative cases are shown in **Figure 6**. The VI_H results of case 1 (**Figure 6A**) by
288 model 2 deemed it a vulnerable lesion ($VI_H = 1.294$). From the histological analysis (**Figure**
289 **6B**), a vulnerable plaque ($VI_P = 1.165$) was confirmed, which was in accordance with model
290 2. Case 2 (**Figure 6C**) revealed also the stable lesion consistently diagnosed by model 2 (VI_H
291 = 0.992), which was further acknowledged by histology ($VI_P = 0.847$) (**Figure 6D**). From the
292 above-mentioned results, it was demonstrated that the utilizing value is a superb predictive
293 tool for determining plaque vulnerability by using the formula model 2 extracted from GdMG
294 NCs enhanced HR-VWI, both non-invasively and quantitatively. The histogram-defined

295 signal dispersion, CV, is a strong predictor for the differentiation of the lesion type for both
296 MCA and BA. Compared with CV, the combination of other parameters including kurtosis,
297 and time did improve the diagnostic power significantly.

298

299 **4.6 BIOCOMPATIBILITY OF GDMG NCS**

300 The Biocompatibility of GdMG NCs in Supplemental Material (*Biocompatibility of GdMG*
301 *NCs and S. Figure 11*) proved that it had no remarkable side impact on tissues, further
302 confirming its prominent biocompatibility, which might carve out the way for its promising
303 future biomedical applications.

304

305 **5. DISCUSSION**

306 A remarkable gain for the accurate assessment of plaque vulnerability was demonstrated by
307 this innovatively designed work through macrophage-targeted enhanced HR-VWI-based
308 histogram analysis. The diagnostic and predictive value of the proposed method in
309 quantitatively distinguishing vulnerable plaques in perfect accordance with the respective
310 histology criteria (pathology vulnerability index) was highlighted. Furthermore, the
311 combination of HR-VWI, macrophage-targeted contrast agent, and histogram analysis can
312 offer a direct mechanistic link to improve the diagnostic reliability objectively, thereby
313 facilitating the clinical translation.

314 The advantages of HR-VWI and the necessity of the macrophage-targeting contrast agents
315 were discussed in Supplemental Material (*Supplemental discussion*)

316 It is a critical-but-challenging task for the current image-evaluation method to provide
317 objective and biologic-accordance information that helps in both clinical diagnosis and
318 management. Growing pieces of evidence have demonstrated the morphological, pathological,
319 and functional properties of the various tissue types that are associated with a high likelihood
320 of plaque rapid progression and rupture²⁰. More specifically, a large LRNC infiltrated by
321 macrophages was prone to rupture, while, on the contrary, collagen, and plaque smooth
322 muscle cell help stabilize the plaque structure. In general, the pathology vulnerability index
323 (VI_p) is considered an important index to screen vulnerable plaques the higher VI_p represents
324 more unstable plaques, whereas a VI_p larger than 1.024 was proved to be vulnerable.
325 “Vulnerable plaque” can be viewed as a function of its composition than size. Meanwhile, the
326 vulnerable plaque relies on image interpretation was diagnosed in previous studies, which
327 may overlook or overestimate some morphological information (lumen stenosis, plaque
328 enhancement, and IPH) due to personal diagnostic experience and understanding of the MR
329 physics in radiology.^{6,21} Hence, to better access the plaque vulnerability, it is vital to
330 emphasize the tissue-specific image properties of the plaque heterogeneity by image
331 interpretation. Inspired by SHI Z. etc., who reported that histogram analysis based on
332 conventional T_1WI image can contribute to differentiating the intracranial plaque type, we
333 expanded their conclusion and finally reached an exciting advance in quantified plaque
334 vulnerability with a statistical method. From the provided statistical analysis, it can be argued

335 that CV has a positive correlation to plaque type, which was also consistent with the
336 literature.²² The underlying reason for vulnerable plaque to exhibit such high CV may be due
337 to the various components in advanced lesions, i.e. necrosis increased due to the impaired
338 ability of macrophages to efferocytose apoptotic cells, and macrophages in advanced lesions
339 also secrete matrix metalloproteinases contributing to fibrous cap thinning and plaque
340 rupture.^{23,24} In addition, GdMG NCs can also generate HR-VWI signal increment when
341 internalized by macrophages. Thus, the ratio of the foamy macrophage in plaque can impact
342 the kurtosis (reflecting the most range of signal intensity)^{25,26}. Skewness also reflects the
343 uneven plaque component distribution by the existence of an asymmetrical shape. For
344 example, the distribution of vascular smooth muscle cell (VSMC) and micro-calcification,
345 both of which may increase the plaque rupture risk.²⁷ Furthermore, the histogram diagram
346 can fully reflect the plaque heterogeneity since the different components have
347 distinguishing signal patterns due to their inherent relaxation rate within the ROI. To the best
348 of our knowledge, our designed experiment is the pioneering workflow to quantitate the
349 plaque vulnerability via histogram based on the macrophage-targeted plaque HR-VWI *in vivo*,
350 which had a satisfactory diagnostic performance with both optimized specificity and
351 sensitivity. Moreover, the proposed analysis processing is generated in Radiant and ImageJ
352 software packages, both of which are in general use and easily available, hence making the
353 introduced method applicable and adjustable for other studies in plaque vulnerability and
354 clinical applications for risk management.

355 Although the high sensitivity of the HR-VWI-based molecular image method permits the

356 detection of subtle morphological and physiological changes of AS plaque with small sample
357 sizes, this animal experiment still suffers from several limitations including essential
358 differences in disease progression from humans, lack of external validation for clinical
359 management, and long duration to assess disease progression.²⁸⁻³⁰ Here, the concept of
360 triangulation by image-evaluating, histology validation, and statistical analysis were applied
361 to increase confidence that an objective exact method was correctly conducted.

362 **6. CONCLUSIONS**

363 The proposed integrative analysis provided an overall picture of the non-invasive nano-image
364 method for quantifying plaque vulnerability and substantially increasing the relevance of the
365 results for clinical reference. The use of GdMG NCs as macrophage-targeted HR-VWI is
366 considered a promising diagnosis avenue for many inflammation-related diseases.
367 Additionally, a deep understanding between the quantified histogram parameters and plaque
368 vulnerability will potentially improve our ability to harness the mechanism for developing
369 novel image strategies against cardiovascular disease and promote the prediction before
370 adverse clinical events. Although this is a proof-of-concept that was only tested in rabbits, it
371 lays a strong foundation for the bench-to-bedside translation of nano-agent-enhanced
372 HR-VWI for stroke risk prediction and prevention.

373 **SOURCES OF FUNDING**

374 This work was funded by the Natural Science Foundation of China (82171916, 81871342),
375 the Natural Scientific Foundation of Tianjin (21CYBJC01580), Tianjin Health Science and

376 technology project (Specific projects of key disciplines) (TJWJ2022XK019), Tianjin Key

377 Medical Discipline (Specialty) Construction Project (TJYXZDXK-041A).

378

379 **DISCLOSURE PARAGRAPH**

380 **1. *Guarantor:***

381 The scientific guarantor of this publication is Shuang Xia.

382 **2. *Conflict of Interest:***

383 The authors of this manuscript declare that they have no relationships with any

384 companies whose products or services may be related to the subject matter of the

385 article.

386 **3. *Statistics and Biometry:***

387 No complex statistical methods were necessary for this paper.

388 **4. *Informed Consent:***

389 Written informed consent was waived by the Institutional Review Board.

390 **5. *Ethical Approval:***

391 This animal study was approved by the Institutional Animal Care and Use Committee

392 of Nankai University (No. 2021-SYDWLL-000425). The study was consistent with

393 regulations for the Administration of Affairs Concerning Experimental Animals of

394 China. There are no ethical/legal conflicts involved in the article.

395 **6. *Study subjects or cohorts overlap:***

396 No study subjects or cohorts have been previously reported.

397 **7. Methodology**

398 • diagnostic or prognostic study

399 • animal experiment

400

401 **KEY POINTS**

402 **QUESTION:** The effectiveness of the Gd-modified macrophage-target gold
403 nanoclusters-based imaging strategy in predicting carotid plaque vulnerability on a
404 medium-sized animal model?

405 **PERTINENT FINDINGS:**

406 **IMPLICATIONS FOR PATIENT CARE:** The development of a nanoparticle-based imaging
407 strategy that can precisely predict carotid plaque vulnerability in a noninvasive manner could
408 potentially improve patient care by allowing for earlier identification and treatment of
409 high-risk plaques, thereby preventing acute vascular events.

410

411 **REFERENCES**

- 412 **1.** Rune I, Rolin B, Lykkesfeldt J. Long-term Western diet fed apolipoprotein E-deficient rats
413 exhibit only modest early atherosclerotic characteristics. *Sci Rep* 2018;8:5416.
- 414 **2.** Saba L, Moody AR, Saam T. Vessel Wall-Imaging Biomarkers of Carotid Plaque
415 Vulnerability in Stroke Prevention Trials: A viewpoint from The Carotid Imaging Consensus
416 Group. *JACC Cardiovasc Imaging* 2020;13:2445-2456.
- 417 **3.** Hoshino T, Sissani L, Labreuche J. Prevalence of Systemic Atherosclerosis Burdens and
418 Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in
419 Stroke With Intracranial Atherosclerotic Disease. *JAMA Neurol* 2018;75:203-211.
- 420 **4.** Goddi A, Bortolotto C, Fiorina I. High-frame rate vector flow imaging of the carotid

- 421 bifurcation. *Insights Imaging* 2017;8:319-328.
- 422 **5.** Mandell DM, Mossa-Basha M, Qiao Y. Intracranial Vessel Wall MRI: Principles and
423 Expert Consensus Recommendations of the American Society of Neuroradiology. *AJNR Am*
424 *J Neuroradiol* 2017;38:218-229.
- 425 **6.** Saba L, Saam T, Jäger HR. Imaging biomarkers of vulnerable carotid plaques for stroke
426 risk prediction and their potential clinical implications. *The Lancet Neurology*
427 2019;18:559-572.
- 428 **7.** Zhao X, Hippe DS, Li R. Prevalence and Characteristics of Carotid Artery High-Risk
429 Atherosclerotic Plaques in Chinese Patients With Cerebrovascular Symptoms: A Chinese
430 Atherosclerosis Risk Evaluation II Study. *J Am Heart Assoc* 2017;6.
- 431 **8.** Kamtchum-Tatuene J, Noubiap JJ, Wilman AH. Prevalence of High-risk Plaques and Risk
432 of Stroke in Patients With Asymptomatic Carotid Stenosis: A Meta-analysis. *JAMA Neurol*
433 2020;77:1524-1535.
- 434 **9.** Amirbekian V, Lipinski M, Briley-Saebo K. Detecting and assessing macrophages in vivo
435 to evaluate atherosclerosis noninvasively using molecular MRI. *Proc Natl Acad Sci U S A*
436 2007;104:961-966.
- 437 **10.** Li X, Wu M, Li J. Advanced targeted nanomedicines for vulnerable atherosclerosis plaque
438 imaging and their potential clinical implications. *Front Pharmacol* 2022;13:906512.
- 439 **11.** Xue, Li, Menglin. Ultrasmall bimodal nanomolecules enhanced tumor angiogenesis
440 contrast with endothelial cell targeting and molecular pharmacokinetics. *Nanomedicine*
441 *Nanotechnology Biology & Medicine* 2019.
- 442 **12.** Wang J, Wu M, Chang J. Scavenger receptor-AI-targeted ultrasmall gold nanoclusters
443 facilitate in vivo MR and ex vivo fluorescence dual-modality visualization of vulnerable
444 atherosclerotic plaques. *Nanomedicine* 2019;19:81-94.
- 445 **13.** Wu M, Li X, Guo Q. Magnetic mesoporous silica nanoparticles-aided dual MR/NIRF
446 imaging to identify macrophage enrichment in atherosclerotic plaques. *Nanomedicine*
447 2020;32:102330.
- 448 **14.** Obaid DR, Calvert PA, Gopalan D. Atherosclerotic plaque composition and classification
449 identified by coronary computed tomography: assessment of computed
450 tomography-generated plaque maps compared with virtual histology intravascular ultrasound
451 and histology. *Circ Cardiovasc Imaging* 2013;6:655-664.
- 452 **15.** Visscher M, Moerman AM, Burgers PC. Data Processing Pipeline for Lipid Profiling of
453 Carotid Atherosclerotic Plaque with Mass Spectrometry Imaging. *J Am Soc Mass Spectrom*
454 2019;30:1790-1800.
- 455 **16.** Senders ML, Hernot S, Carlucci G. Nanobody-Facilitated Multiparametric PET/MRI
456 Phenotyping of Atherosclerosis. *JACC Cardiovasc Imaging* 2019;12:2015-2026.
- 457 **17.** Zhang Z, Jiang Y, Zhou Z. Scavenger receptor A1 attenuates aortic dissection via
458 promoting efferocytosis in macrophages. *Biochem Pharmacol* 2019;168:392-403.
- 459 **18.** Gong Y, Cao C, Guo Y. Quantification of intracranial arterial stenotic degree evaluated by
460 high-resolution vessel wall imaging and time-of-flight MR angiography: reproducibility, and
461 diagnostic agreement with DSA. *Eur Radiol* 2021.
- 462 **19.** Cao Y, Xiao X, Liu Z. Detecting vulnerable plaque with vulnerability index based on

- 463 convolutional neural networks. *Comput Med Imaging Graph* 2020;81:101711.
- 464 **20.** Eslami P, Hartman EMJ, Albaghadai M. Validation of Wall Shear Stress Assessment in
465 Non-invasive Coronary CTA versus Invasive Imaging: A Patient-Specific Computational
466 Study. *Ann Biomed Eng* 2021;49:1151-1168.
- 467 **21.** Song JW, Pavlou A, Xiao J. Vessel Wall Magnetic Resonance Imaging Biomarkers of
468 Symptomatic Intracranial Atherosclerosis: A Meta-Analysis. *Stroke* 2021;52:193-202.
- 469 **22.** Shi Z, Li J, Zhao M. Quantitative Histogram Analysis on Intracranial Atherosclerotic
470 Plaques: A High-Resolution Magnetic Resonance Imaging Study. *Stroke* 2020;51:2161-2169.
- 471 **23.** Michel JB, Lagrange J, Regnault V. Conductance Artery Wall Layers and Their
472 Respective Roles in the Clearance Functions. *Arterioscler Thromb Vasc Biol*
473 2022;42:e253-e272.
- 474 **24.** Burtea C, Ballet S, Laurent S. Development of a Magnetic Resonance Imaging Protocol
475 for the Characterization of Atherosclerotic Plaque by Using Vascular Cell Adhesion
476 Molecule-1 and Apoptosis-Targeted Ultrasmall Superparamagnetic Iron Oxide Derivatives.
477 *Arteriosclerosis Thrombosis and Vascular Biology* 2012;32:E36-+.
- 478 **25.** Trivedi RA, Mallawarachi C, JM UK-I. Identifying inflamed carotid plaques using in
479 vivo USPIO-enhanced MR imaging to label plaque macrophages. *Arterioscler Thromb Vasc*
480 *Biol* 2006;26:1601-1606.
- 481 **26.** Howarth SPS, Tang TY, Trivedi R. Utility of USPIO-enhanced MR imaging to identify
482 inflammation and the fibrous cap: A comparison of symptomatic and asymptomatic
483 individuals. *Eur J Radiol* 2009;70:555-560.
- 484 **27.** Durham AL, Speer MY, Scatena M. Role of smooth muscle cells in vascular calcification:
485 implications in atherosclerosis and arterial stiffness. *Cardiovasc Res* 2018;114:590-600.
- 486 **28.** Beldman TJ, Senders ML, Alaarg A. Hyaluronan Nanoparticles Selectively Target
487 Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. *Acs Nano*
488 2017;11:5785-5799.
- 489 **29.** Karel M, Hechler B, Kuijpers M. Atherosclerotic plaque injury-mediated murine
490 thrombosis models: advantages and limitations. *Platelets* 2020;31:439-446.
- 491 **30.** Zhou Y, Zhang NR, Zheng ZN. Regular transient limb ischemia prevents atherosclerosis
492 progression in hypercholesterolemic rabbits. *Chin Med J (Engl)* 2019;132:1079-1086.

493

494


495

496

497

498

499 **FIGURES AND LEGENTS**



500


501 Schematic outlining the synthesis of PP1-Au@GSH@Gd NCs (GdMG NCs) and the strategy

502 for plaque vulnerability prediction.

503

504

505



506

507 **Figure 1** Construction of Atherosclerotic Rabbit Model. The experimental timeline (A)

508 includes a one-week regular diet, a one-week atherogenic diet before the injury, balloon

509 injury, and atherogenic feeding before euthanasia. The blood lipid disorder (B) (TC: total

510 cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C:


511 low-density lipoprotein) were induced by high-fat diet (HFD) and the body weight (C) keep

512 increasing during the experiment session. Gross lesions of the aorta and carotid artery, and

513 stained by Oil red O (visualized as a red area on face) (D) shows the atherosclerosis change.

514 Serial paraffin cross-sections of the carotid artery were stained with Oil red O (E) revealing

515 the growth of plaque lipid content over time.



516

517 **Figure 2** In vivo target ability of GdMG NCs in atherosclerotic rabbits. The vessel wall
518 images of atherosclerotic rabbit carotid artery before and after the injection of contrast agent
519 (highlighted within a yellow box). (A) The traditional TOF-MRA clarifies the vessel diameter
520 to measure the severity of atherosclerosis (yellow arrowhead). (B) Contrast-enhanced
521 HR-VWI, from which GdMG NCs were able to identify a higher eccentric plaque signal on
522 the axis section image (red arrowhead), while Gadovist only showed the vessel wall
523 thickening with circumferential enhancement (yellow dotted box). The contrast to noise ratio
524 (CNR) (C) GdMG NCs was significantly higher than that of Gadovist ($p < 0.05$). The
525 histology assessment of the stenotic lesions was conducted for the validation of the GdMG
526 NCs targeting capability to macrophages in plaque (D). Abundant lipid deposits were shown
527 by Oil red O staining, confirming that the enhanced areas were definite plaque sites;
528 over-expression of CD68 and SR-AI were detected by IHC staining, indicating the foamy

529 macrophages tremendously enriched in plaque area (black arrow); the extensive presence of
530 GdMG NCs deposition in plaque was validated by silver-staining (black arrow), which
531 further providing strong shreds of evidence to the compelling targeting capacity of GdMG
532 NCs to atherosclerotic plaques.

533

534

535

536

537

538

539

540

541

542

543

544


545

546

547

548

549



550

551 **Figure 3** Dynamic changes of wall area (WA) and plaque area (PA) of atherosclerotic rabbit's
 552 carotid artery by contrast-enhanced HR-VWI with GdMG NCs. (A) Schematic segmentation
 553 of HR-VWI. The control case showed a cross-section image of normal rabbit LCCA with
 554 smooth, round and non-stenotic lumen inner-surface. As can be ascertained, the
 555 crescent-shaped hyperintense signal (representing PA, red line) enhanced by the presence of

556 GdMG NCs was significantly higher than Gadovist, rendering the clearer plaque delineation.

557 Besides, the eccentric iso- and slightly hyperintense signal representing WA (area between

558 yellow and green circle) could also be easily delineated by the incorporated GdMG NCs with

559 sharp demarcation. While after the Gadovist administration, WA presented a heterogeneous

560 annular enhancement region with blurred boundaries, in which the existence of a relatively

561 ambiguous contrast-enhanced spot (recorded as PA) could be barely outlined manually. (B)

562 The cross-section images represent a crescent-shaped hyperintense signal (representing PA)

563 enhanced by GdMG NCs was significantly higher than Gadovist (red arrowhead). The

564 dynamic progression of plaque WA (C) and PA (D) was illustrated according to the

565 contrast-enhanced HR-VWI with Gadovist and GdMG NCs. H&E-staining sections (E)

566 determine the true histological PA and WA at different plaque stages. The percentile for the

567 rated difference between contrast-enhanced HR-VWI to pathology is shown in mountain

568 plots (F, G). The GdMG NCs curve (red dot-dash-line) is steeply centered around zero,

569 indicating a small divergence from histology than Gadovist (black dot-dash-line).

570 Bland-Altman plot (H) shows the comparison of the inter-observer agreement for

571 contrast-enhanced HR-VWI evaluation. GdMG NCs could offer a more satisfying diagnostic

572 agreement than Gadovist, since GdMG NCs have less inter-observer difference (red dots, $p >$


573 0.05) than Gadovist (purple dots, $p < 0.05$). $*p < 0.05$, $n = 6$ biologically independent animals

574 in different plaque stages. $*p < 0.05$, Bonferroni adjustment for multiple comparisons, $n = 6$


575 biologically independent animals in each time point. The data are presented as mean \pm SEM.

576 RM ANOVA with Bonferroni's post hoc test.


A. Model construction and test



B. Application and validation



C. The novel method for plaque vulnerability



577


578 **Figure 4** Flowchart of the *in vivo*, non-invasive and quantitative characterization of plaque

579 vulnerability and the final performance evaluation in the work.

580

581

582



583

584 **Figure 5** Non-invasive Plaque vulnerability prediction by GdMG NCs enhanced HR-VWI
 585 images and histogram analysis. The histogram analysis (A) of plaque (yellow dot-line)
 586 according to contrast-enhanced HR-VWI with Gadovist and GdMG NCs. The signal
 587 distribution features are described by skewness (asymmetrical shape), and kurtosis
 588 (sharpness), and CV describes the dispersion of signal intensity. The serial co-registered
 589 histology tests (B) are quantified and analyzed to calculate the pathology vulnerability index
 590 (VI_P) for distinguishing vulnerable plaques ($VI_P \geq 1.024$) from stable plaques ($VI_P < 1.024$).
 591 Box plots (C) showed the difference in the histogram parameters and signal intensity features
 592 between stable (n = 17) and vulnerable plaque (n = 13), evaluated on contrast-enhanced
 593 HR-VWI ($p < 0.05$). 3D The scatter plots (D) describe the relationship among kurtosis,
 594 skewness and CV, with the color mapping representing the VI_P value and the scatter diameter
 595 representing the plaque area. The fitting formula based on the multiple linear regression

596 model (E) offers a theory for calculating the VI_P from the contrast-enhanced HR-VWI *in vivo*.

597 The fitting formula from the GdMG NCs (model 2) committed a better diagnosis prediction

598 for vulnerable plaque. Besides, CV showed a significant correlation to VI_P ($p < 0.05$).

599

600

601

602

603

604

605

606

607

608

609

610

611


612

613

614

615

616



617

618 **Figure 6** The validation of the diagnostic value of the GdMG NCs enhanced HR-VWI. (A)





619 Histogram vulnerability index (VI_H) was calculated based on contrast-enhanced HR-VWI






620 with Gadovist and GdMG NCs. (B) Pathology vulnerability index (VI_P) calculated as the

621 gold criteria for plaque vulnerability. (C) Receiver operating characteristic curve for

622 evaluating our prediction models. The area under curve (AUC) represents the proposed fitting


623 formula, especially model 2 has a perfect diagnostic performance.





A. Model construction and test

Histological analysis for Pathology vulnerability index (VI_P) as gold standard



Histological analysis


Pathology vulnerability index (VI_P)

Plaque type

Vulnerable


Stable

Histogram analysis for plaque vulnerability




Histogram analysis

Histogram vulnerability index (VI_H) based on histogram



Best fitted model for VI_H by ROC




Diagnostic performance

Histogram vulnerability index (VI_H)

B. Application and validation

Histogram analysis for plaque vulnerability *in vivo*



Histogram analysis


Histogram vulnerability index (VI_H)

Plaque type

Vulnerable

Stable


Histological analysis for Pathology vulnerability index (VI_P) as gold standard




Histological analysis

Pathology vulnerability index (VI_P)




C. The novel method for plaque vulnerability



Non-invasive image feature




Quantified histology features





F

The fitted equation to predict the VI_H from histogram-derived parameter

Model	p	Adjusted R^2	Formula
1	< 0.001	0.775	$VI_H = 0.090 + 2.534CV$
2	< 0.001	0.940	$VI_H = 0.118 + 3.073CV - 0.025Kurtosis$



Representative case 1



Representative case 2

